- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Solid Biosciences Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://solidbio.com
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: Alexander Gery Cumbo
Number Of Employees: 100
Enterprise Value: $38,523,776
PE Ratio: -1.21
Exchange/Ticker 1: NASDAQ:SLDB
Exchange/Ticker 2: N/A
Latest Market Cap: $275,875,104
BioCentury | Mar 19, 2025
Market Access
Patient death resurfaces safety concerns for Sarepta’s gene therapy
But it’s unclear that market access will be affected
BioCentury | Feb 21, 2025
Finance
Antiviral, oncology company Genuine plots Hong Kong listing: Public Equity Report
Plus: Xtalpi, Solid and Arcus all raise cash
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | May 20, 2024
Management Tracks
Chroma hires Jenny Marlowe as CDO
Plus: William Elder named CFO of CervoMed, and updates from Xspray and Senti
BioCentury | Mar 12, 2024
Deals
Deal report: Boehringer-Sosei pursuing new schizophrenia target
Plus: Gilead- Merus to develop trispecific T cell engagers for cancer, and Armatus-Solid collab
BioCentury | Nov 15, 2023
Management Tracks
Rivus appoints Smith as chair and hires Schott as CMO
Plus: Noema and K36 hire CMOs and more from Myricx, Outlook and IMIDomics
BioCentury | Apr 14, 2023
Management Tracks
Editas names Reeve chair, adds Levy to board
Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more
BioCentury | Mar 28, 2023
Product Development
Gene therapy: If you’re not first, are you last?
How gene therapy CEOs are thinking about the competitive landscape, and where market opportunity exists
BioCentury | Mar 21, 2023
Management Tracks
Debra Yu joins Panacea as partner, COO
Plus: Sonata hires Kite veteran Marincola as CSO and updates from Ascidian, Olink, Azafaros, Akoya and more
Items per page:
1 - 10 of 66